HBM Holdings Limited (HKG:2142)
14.37
-0.07 (-0.48%)
Sep 10, 2026, 11:59 AM HKT
HBM Holdings Revenue
HBM Holdings had revenue of $122.49M USD in the half year ending June 30, 2026, with 416.82% growth. This brings the company's revenue in the last twelve months to $179.15M, up 54.82% year-over-year. In the year 2025, HBM Holdings had annual revenue of $157.98M with 314.63% growth.
Revenue (ttm)
$179.15M
Revenue Growth
+54.82%
P/S Ratio
8.92
Revenue / Employee
$547.86K
Employees
327
Market Cap
12.53B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 157.98M | 119.88M | 314.63% |
| Dec 31, 2024 | 38.10M | -51.40M | -57.43% |
| Dec 31, 2023 | 89.50M | 48.84M | 120.13% |
| Dec 31, 2022 | 40.66M | 36.35M | 843.80% |
| Dec 31, 2021 | 4.31M | -9.80M | -69.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Everest Medicines | 2.78B |
| Duality Biotherapeutics | 972.22M |
| Ascentage Pharma Group International | 741.90M |
| Suzhou Ribo Life Science | 536.18M |
| CStone Pharmaceuticals | 490.92M |
| Metis TechBio | 298.03M |
| Nanjing Leads Biolabs | 246.16M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
HBM Holdings News
- 13 days ago - HBM Holdings Earnings release: H1 2026 - Filings
- 5 months ago - HBM Holdings Earnings release: H2 2025 - Filings
- 5 months ago - HBM Holdings Annual report: H2 2025 - Filings
- 5 months ago - HBM Holdings Slides: H2 2025 - Filings